An apt and accurate illustration of the professional regulation of medicine in 2016 via Mel Brooks History of the World Part 1

goodtobeking

It’s good to be the king!

Count De Monet: I have come on the most urgent of business. It is said that the people are revolting!
King Louis: You said it; they stink on ice.

countdemonet_thumb

Count de Monet: Gerald! Gerald: Count da Money! Count de Monet: de Monet… Monet! Say it! Monet! Gerald and Count de Monet: Moonnet, Moonnet, Moonnet Gerald, Count de Monet, Bearnaise: Mooonnnet! Count de Monet: Perfect, don’t forget! Give it to me again! Monet. Gerald and Bernaise: Monet.

Impoverished Paris Street Merchant: Rats, rats for sale. Get your rats. Good for rat stew, rat soup, rat pies, or the ever-popular ratatouille.

Other Street Merchant: Nothing, I have absolutely nothing for sale!
maxresdefault

The Brain Disease Model of Addiction: is it Supported by the Evidence and has it Delivered on its Promises?

Dr. Allwissend 01

The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?

Prof Wayne Hall, PhD
Adrian Carter, PhD
Cynthia Forlini, PhD

Sign up for Lancet Psychiatry to read the full article. An overview is below.

We need a similar critique of the American Society of Addiction Medicine (ASAM)  and its affiliates on this side of the Atlantic as “addiction medicine” is slated to be approved  by the  American Board of Medical Specialties in 2016 even though the discipline falls far short of the educational and professional standards for quality practice developed and implemented by all other ABMS member boards.    According to the ABMS these 24 boards are:

“committed to the principle of examining doctors based on six general competencies designed to encompass quality care: patient care, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice.”

These areas have been collectively identified by the ABMS, the American College of Graduate Medical Education (ACGME) and the Institute of Medicine (IOM) in order to standardize graduate medical education.

Any critique of the ASAM would find a number of issues antithetical to the six general competencies which stress “learning and improvement.”   In contrast the ASAM rests on the conviction that their views are absolutely certain and patently rejects open-minded inquiry.  An academic analysis of addiction medicine  from the vantage point of the ASAM would reveal false assumptions, bias, dogmatism, and data-dredging.  It would also reveal that those claiming expertise are in fact illegitimate and irrational authority who believe in an ends-justifies-the-means approach to push forth the chronic relapsing brain disease with lifelong abstinence an d imposed 12-step recovery. These are false experts who rationalize unethical, unprofessional and even criminal behavior as zeal for the faith if it aligns with the brain disease model of addiction (BDMA)   Their viewpoints are fixed and final.

They have not been held to truly objective judging, analysis, evaluation or outside critique.  The purpose of critique is the same as the purpose of critical thinking: to appreciate strengths as well as weaknesses, virtues as well as failings. Critical thinkers critique in order to redesign, remodel, and make better. This direly needs to be done.  The evidence-base for both the BDMA and the drug and alcohol testing, assessment and treatment is poor.     They are claiming physician health programs are the crown jewel of addiction treatment– a replicable model to be replicated in other populations.  It is all hyperbole and propaganda.  In reality they are using medical assessment and treatment as tools to repress and punish doctors.  Those running the state physician health programs are typically morally disengaged bullies with Machiavellian egocentricity.   And all the congratulatory backslapping is based on a singe poorly designed opinion piece.

Science and medicine need to be predicated on competence, thoughtfulness, good faith, civility, honesty, and integrity. This is universally applicable.  What they are doing betrays the trust of society and breaches the most basic ethical obligations of not only doctors but human beings.

But no one seems to be challenging them. Why is no one questioning this self-appointed authority. If people do not start talking, writing, discussing and debating the current paradigm then what Robert Dupont describes in the ASAM White Paper on Drug Testing will be ushered in.  As with doctors you won’t know it until it hits you.    If the ASAM becomes an ABMS medical specialty then it will be too late. They will impose their authority on you as a patient and their won’t be a damn thing you will be able to do about it.

Once illegitimate and irrational authority are sanctified by the American Board of Medical Specialties there will be nothing left to do except watch the profession of medicine go up in flames.

Right now it’s just doctors and pilots.   What you need to see is that you are next.  I base that prediction on past public-policy, regulatory, administrative and medical practice tinkering as well as the documented paper trail of “research” and opinion. And even though all of this can be explained using documentary evidence, fact and critical analysis no one seems alarmed.

If you map it out you will see the trajectory is aimed at the transportation industry,  students with federal loans,  high school athletes, schools, gun owners, and eventually schools.

If you have something to lose that is affiliated with a state or federal agency they will hold it hostage if you get a positive hair, nail, sweat blood, or urine test at your doctors visit.    The positive test is the golden ticket for them and a ticket to an assessment facility in Kansas, Arkansas, Mississippi and some other places for you on your dime.    And these are one-way tickets. No return to normality available.  One way ticket.    No return flight.

See full article through the following link:

http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(14)00126-6/fulltext

Screen Shot 2014-12-30 at 2.10.24 AM


Proponents of the brain disease model of addiction (BDMA) have been very influential in setting the funding priorities of NIDA, and by extension the bulk of publicly supported research on addiction. In 1998, Leshner testified that NIDA supports more than 85% of the world’s research on drug abuse and addiction.3 The American Society of Addiction Medicine has defined addiction as a “primary, chronic disease of brain reward, motivation, memory, and related circuitry”.4 In July, 2014, newly appointed Acting Director of US National Drug Control Policy, Michael Botticelli, launched a reformist strategy nationally, claiming decades of research have demonstrated that addiction is a brain disorder—one that can be prevented and treated.5 The BDMA has also been widely discussed in leading scientific research journals3, 6 and most recently in a positive editorial in Nature.7

In the USA, proponents of the BDMA have argued that it will help to deliver more effective medical treatments for addiction with the cost covered by health insurance, making treatment more accessible for people with addictions.1, 2, 6 An increased acceptance of the BDMA is also predicted to reduce the stigma associated with drug addiction by replacing the commonly held notion that people with drug addiction are weak or bad with a more scientific viewpoint that depicts them as having a brain disease that needs medical treatment.

In this Personal View, we critically assess the scientific evidence for the BDMA reported in leading general scientific journals and the extent of the social benefits that advocates of the BDMA claim it has produced, or is likely to produce, with its widespread acceptance among clinicians, policy makers, and the public. The BDMA is not co-extensive with neuroscience-based explanations of addiction. This review is not intended as a critique of all neuroscience research on addiction. We focus instead on the popular simplification of work in this specialty that has had a major influence on popular discourse on addiction in scientific journals and mainstream media.


images-3Conclusions

Considerable scientific value exists in the research into the neurobiology and genetics of addiction, but this research does not justify the simplified BDMA that dominates discourse about addiction in the USA and, increasingly, elsewhere. Editors of Nature were mistaken in their assumption that the BDMA represents the consensus view in the addictions specialty,7 as shown by a letter signed by 94 addiction researchers and clinicians (including one of the authors of this Personal View).74Understanding of addiction, and the policies adopted to treat and prevent problem drug use, should give biology its due, but no more than it is due. Chronic drug use can affect brain systems in ways that might make cessation more difficult for some people. Economic, epidemiological, and social scientific evidence shows that the neurobiology of addiction should not be the over-riding factor when formulating policies toward drug use and addiction.

The BDMA has not helped to deliver the effective treatments for addiction that were originally promised by Leshner and its effect on public health policies toward drug addiction has been modest. Arguably, the advocacy of the BDMA led to overinvestment by US research agencies in biological interventions to cure addiction that will have little effect on drug addiction as a public health issue. Increased access to more effective treatment for addiction is a worthy aim that we support but this aim should not be pursued at the expense of simple, cost effective, and efficient population-based policies to discourage the whole population from smoking tobacco and drinking heavily. Nor should the pursuit of high technology cures distract from the task of increasing access to available psychosocial and drug treatments for addiction, which most people with addictive disorder are still unable to access.

Our rejection of the BDMA is not intended as a defence of the moral model of addiction.65 We share many of the aspirations of those who advocate the BDMA, especially the delivery of more effective treatment and less punitive responses to people with addiction issues. Addiction is a complex biological, psychological, and social disorder that needs to be addressed by various clinical and public health approaches.65 Research into the neuroscience of addiction has provided insights into the neurobiology of decision-making, motivation, and behavioural control in addiction. Chronic use of addictive drugs can impair cognitive and motivational processes and might partly explain why some people are more susceptible than others to developing an addiction. The challenge for all addiction researchers—including neurobiologists—is to integrate emerging insights from neuroscience research with those from economics, epidemiology, sociology, psychology, and political science to decrease the harms caused by drug misuse and all forms of addiction.46

Slide09


References

  1. Leshner, A. Addiction is a brain disease, and it matters. Science. 1997; 278: 45–47
  2. Dackis, C and O’Brien, C. Neurobiology of addiction: treatment and public policy ramifications.Nat Neurosci. 2005; 8: 1431–1436
  3. US Government Printing Office. Senate Hearing 105-573. Drug addiction and recovery.http://www.gpo.gov/fdsys/pkg/CHRG-105shrg49670/html/CHRG-105shrg49670.html. ((accessed Sept 26, 2014).)
  4. American Society of Addiction Medicine. Public policy statement: definition of addiction. Chevy Chase, MD. http://www.webcitation.org/62jXWo8dq; 2011. ((accessed July 15, 2014).)
  5. Botticelli, M. National blueprint for drug policy reform released today in Roanoke, VA. Office of National Drug Control Policy media release July 9, 2014.http://www.whitehouse.gov/blog/2014/07/09/national-blueprint-drug-policy-reform-released-today-roanoke-va. ((accessed July 15, 2014).)
  6. Volkow, N and Li, T. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci.2004; 5: 963–970
  7. Animal farm. Nature. 2014; 506: 5
  8. Ahmed, S. The science of making drug-addicted animals. Neuroscience. 2012; 211: 107–125
  9. Koob, G. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis.Addiction. 2006; 101: 23–30
  10. Feltenstein, M and See, R. The neurocircuitry of addiction: an overview. Br J Pharmacol. 2008;154: 261–274
  11. Hyman, S, Malenka, R, and Nestler, E. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci. 2006; 29: 565–598
  12. Koob, G and Le Moal, M. Neurobiology of addiction. Academic Press, New York; 2006
  13. Panlilio, L and Goldberg, S. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction. 2007; 102: 1863–1870
  14. Vanderschuren, L and Ahmed, S. Animal studies of addictive behavior. Cold Spring Harb Perspect Med. 2013; 3: a011932
  15. Volkow, N, Wang, G, Fowler, J, Tomasi, D, and Baler, R. Neuroimaging of addiction. in: P Seeman, B Madras (Eds.) Imaging of the human brain in health and disease. Elsevier, San Diego; 2014: 1–26
  16. Volkow, N, Fowler, J, Wang, G, Teland, F, and Baler, R. Imaging dopamine’s role in drug abuse and addiction. in: L Iversen, S Iversen, S Dunnett, A Bjorklund (Eds.) Dopamine handbook. Oxford University Press, Oxford; 2010: 407–417
  17. Volkow, N and Baler, R. Addiction science: uncovering neurobiological complexity.Neuropharmacology. 2014; 76: 235–249
  18. Volkow, N, Fowler, J, Wang, G, Baler, R, and Telang, F. Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology. 2009; 56: 3–8
  19. Reske, M and Paulus, M. A neuroscientific approach to addiction: ethical issues. in: J Illes, B Sahakian (Eds.) Oxford handbook of neuroethics. Oxford University Press, Oxford; 2011: 177–202
  20. Kendler, K, Chen, X, Dick, D et al. Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci. 2012; 15: 181–189
  21. Ball, D. Addiction science and its genetics. Addiction. 2008; 103: 360–367
  22. Satel, S and Lilienfeld, S. Brainwashed: the seductive appeal of mindless neuroscience. Perseus Books Group, New York; 2013
  23. Heyman, G. Addiction: a disorder of choice. Harvard University Press, Cambridge, MA; 2009
  24. Kincaid, H and Sullivan, J. Medical models of addiction. in: D Ross, H Kincaid, D Spurrett, P Collins (Eds.) What is addiction?MIT, Cambridge, MA; 2010: 353
  25. Robins, L, Helzer, J, Hesselbrock, M, and Wish, E. Vietnam veterans three years after Vietnam: how our study changed our view of heroin. Am J Addict. 2010; 19: 203–211
  26. Kleiman, M. When brute force fails: how to have less crime and less punishment. Princeton University Press, Princeton; 2009
  27. Bachman, J, Wadsworth, K, O’Malley, P, Johnston, L, and Schulenberg, J. Smoking, drinking, and drug use in young adulthood: the impacts of new freedoms and new responsibilities. Lawrence Erlbaum, Mahwah, NJ; 1997
  28. Ahmed, S, Lenoir, M, and Guillem, K. Neurobiology of addiction versus drug use driven by lack of choice. Curr Opin Neurobiol. 2013; 23: 581–587
  29. Alexander, B, Coambs, R, and Hadaway, P. The effect of housing and gender on morphine self-administration in rats. Psychopharmacology (Berl). 1978; 58: 175–179
  30. Hall, WD, Gartner, CE, and Carter, A. The genetics of nicotine addiction liability: ethical and social policy implications. Addiction. 2008; 103: 350–359
  31. Gartner, CE, Barendregt, J, and Hall, WD. Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction. 2009; 104: 118–126
  32. Roberts, N, Vogelstein, J, Parmigiani, G, Kinzler, K, Vogelstein, B, and Velculescu, V. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012; 4: 133ra58
  33. Button, K, Ioannidis, J, Mokrysz, C et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013; 14: 365–376
  34. Ioannidis, J. Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry. 2011; 68: 773–780
  35. Ioannidis, J, Munafò, M, Fusar-Poli, P, Nosek, B, and David, S. Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. Trends Cogn Sci. 2014; 18: 235–241
  36. Hall, WD, Gartner, CE, Mathews, R, and Munafò, M. Technical, ethical and social issues in the bioprediction of addiction liability and treatment response. in: A Carter, W Hall, J Illes (Eds.)Addiction neuroethics: The ethics of addiction research and treatment. Elsevier, New York; 2012:116–138
  37. Lingford-Hughes, A, Welch, S, Peters, L, and Nutt, D. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012; 26: 899–952
  38. Ersche, K, Williams, G, Robbins, T, and Bullmore, E. Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol. 2013; 23: 615–624
  39. Hyman, S. The neurobiology of addiction: implications for the voluntary control of behaviour. in:J Illes, B Sahakian (Eds.) Oxford handbook of neuroethics. Oxford University Press, Oxford; 2011:203–217
  40. Goldstein, R and Volkow, N. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011; 12: 652–669
  41. Volkow, N, Wang, G, Fowler, J, and Tomasi, D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012; 52: 321–326
  42. National Institute on Drug Abuse. Drugs, brains and behavior: the science of addiction. Washington, DC. http://www.drugabuse.gov/publications/science-addiction; 2007. ((accessed July 15, 2014).)
  43. Nutt, D and Lingford-Hughes, A. Addiction: the clinical interface. Br J Pharmacol. 2008; 154: 397–405
  44. Volkow, N and Li, T. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther. 2005; 108: 3–17
  45. Lingford-Hughes, A, Watson, B, Kalk, N, and Reid, A. Neuropharmacology of addiction and how it informs treatment. Br Med Bull. 2010; 96: 93–110
  46. Kalant, H. What neurobiology cannot tell us about addiction. Addiction. 2010; 105: 780–789
  47. Koob, G, Lloyd, G, and Mason, B. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat Rev Drug Discov. 2009; 8: 500–515
  48. Cahill, K, Stead, L, and Lancaster, T. Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2011; 2 (CD006103.)
  49. Rösner, S, Hackl-Herrwerth, A, Leucht, S, Lehert, P, Vecchi, S, and Soyka, M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010; 9 (CD004332.)
  50. Minozzi, S, Amato, L, Vecchi, S, Davoli, M, Kirchmayer, U, and Verster, A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011; 4 (CD001333.)
  51. Kosten, T, Domingo, C, Shorter, D et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014; 140: 42–47
  52. Hartmann-Boyce, J, Cahill, K, Hatsukami, D, and Cornuz, J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012; 8 (CD007072.)
  53. Hall, WD and Gartner, CE. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Curr Opin Psychiatry. 2011; 24: 191–196
  54. Paul, S, Mytelka, D, Dunwiddie, C et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010; 9: 203–214
  55. Djulbegovic, B, Hozo, I, and Ioannidis, J. Improving the drug development process: more not less randomized trials. JAMA. 2014; 311: 355–356
  56. Prinz, F, Schlange, T, and Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov. 2011; 10: 712
  57. Tsilidis, K, Panagiotou, O, Sena, E et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 2013; 11: e1001609
  58. Hall, WD. Stereotactic neurosurgical treatment of addiction: minimising the chances of another ‘great and desperate cure’. Addiction. 2006; 101: 1–3
  59. Luigjes, J, van den Brink, W, Feenstra, M et al. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry. 2012; 17: 572–583
  60. Stephen, J, Halpern, C, Barrios, C et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.Addiction. 2012; 107: 624–634
  61. Rouaud, T, Lardeux, S, Panayotis, N, Paleressompoulle, D, Cador, M, and Baunez, C. Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proc Natl Acad Sci USA.2010; 107: 1196–1200
  62. Carter, A and Hall, WD. Proposals to trial deep brain stimulation to treat addiction are premature. Addiction. 2011; 106: 235–237
  63. Baltuch, G and Stern, M. Deep brain stimulation for Parkinson’s disease. Informa Healthcare,New York; 2007
  64. Rose, G. The strategy of preventive medicine. Oxford University Press, Oxford; 1992
  65. Carter, A and Hall, WD. Addiction neuroethics: the promises and perils of neuroscience research on addiction. Cambridge University Press, London; 2012
  66. National Institute on Drug Abuse. Fiscal Year 2015 Budget information—congressional justification for National Institute on Drug Abuse. Rockville, MD. http://www.drugabuse.gov/about-nida/legislative-activities/budget-information/fiscal-year-2015-budget-information-congressional-justification-national-institute-drug-abuse; 2014. ((accessed July 15, 2014).)
  67. White, V, Hill, D, Siahpush, M, and Bobevski, I. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control. 2003; 12: ii67
  68. Pierce, J, Gilpin, E, Emery, S, White, M, Rosbrook, B, and Berry, C. Has the California tobacco control program reduced smoking?. JAMA. 1998; 280: 893
  69. Hall, WD, Madden, P, and Lynskey, M. The genetics of tobacco use: methods, findings and policy implications. Tob Control. 2002; 11: 119–124
  70. Doran, C, Hall, WD, Shakeshaft, A, Vos, T, and Cobiac, L. Alcohol policy reform in Australia: what can we learn from the evidence. Med J Aust. 2010; 192: 468–470
  71. Miller, P, Carter, A, and De Groot, F. Investment and vested interests in neuroscience research of addiction: why research ethics requires more than informed consent. in: A Carter, W Hall, J Illes (Eds.) Addiction neuroethics: the ethics of addiction research and treatment. Elsevier, New York;2012: 278–301
  72. Courtwright, D. The NIDA brain-disease paradigm: history, resistance, and spinoffs. BioSocieties.2010; 5: 137–147
  73. Nutt, D, King, L, Saulsbury, W, and Blakemore, C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007; 369: 1047–1053
  74. Heim, D. Addiction: not just brain malfunction. Nature. 2014; 507: 40

Physician Suicide, Organizational Justice and the “Cry of pain” Model: Hopelessness, Helplessness and Defeat

tireddoctorAccording to Talbott, “impaired doctors must first acknowledge their addiction and overcome their ‘terminal uniqueness’ before they can deal with a drug or alcohol problem.” “Terminal uniqueness “ is a phrase Talbott uses to describe doctors’ tendency to think they can heal themselves. “M-Deity” refers to doctors “being trained to think they’re God,” an unfounded generalization considering the vast diversity of individuals that make up our profession. This attitude, according to some critics, stems from the personal histories of the treatment staff, including Talbott, who are recovering alcoholics and addicts themselves. One such critic was Assistant Surgeon General under C. Everett Koop John C. Duffy who said that Ridgeview suffered from a “boot-camp mentality” toward physicians under their care and “assume every physician suffering from substance abuse is the same lying, stealing, cheating, manipulating individual they were when they had the illness. Certainly some physicians are manipulative, but it’s naïve to label all physicians with these problems.”

mllangan1's avatarDisrupted Physician

They can be a terror to your mind and show you how to hold your tongue
They got mystery written all over their forehead
They kill babies in the crib and say only the good die young
They don’t believe in mercy
Judgement on them is something that you’ll never see
They can exalt you up or bring you down main route
Turn you into anything that they want you to be–Bob Dylan, Foot of Pride


Screen Shot 2015-04-30 at 2.55.32 AM

Although no reliable statistics yet exist, anecdotal reports suggest a marked rise in physician suicide in recent years. From the reports I am receiving it is a lot more than the oft cited “medical school class” of 400 per year.

This necessitates an evaluation of predisposing risk factors such as substance abuse and depression, but also requires a critical examination of what external forces may be involved in the descent from suicidal ideation to suicidal…

View original post 4,152 more words

The Irrational Authority

imgres-24

The Irrational Authority.  Originally posted on:

Chaos Theory and Pharmacology

A blog dedicated to the study of complex relationships in pharmacology. “Journalism is printing what someone else does not want printed: everything else is public relations.” ― George Orwell

The Irrational Authority

Goodle F. Re: ‘Drug Policy: We Need Brave Politicians and Open Minds
The BMJ. December 17, 2014.

Drug policy: we probably need an “irrational authority”

“One thing is for certain. When society gives power of diagnosis and treatment to individuals
within a group schooled in just one uncompromising model of addiction with the majority attributing their very own sobriety to that model, they will exercise that power to diagnose and treat anyone and everyone according to that model. The birth of Addiction Medicine as an ABMS accepted discipline is sure to be a success for the drug and alcohol testing and 12-step treatment industry, but its spawn is sure to be an inauspicious mark on the Profession and Guild of Medicine and a bane of society for years to come.” ―Michael Lawrence Langan.(1)

References

1. DISRUPTED PHYSICIAN 101.2: “ADDICTION MEDICINE” IS A SELF-DESIGNATED PRACTICE SPECIALTY UNRECOGNIZED BY THE AMERICAN BOARD OF MEDICAL SPECIALTIES–(AN AMA CENSUS TERM INDICATING NEITHER TRAINING NOR COMPETENCE).
URL: http://disruptedphysician.com/2014/11/21/disrupted-physician-101-3-addic… (date accessed: December 17, 2014).

Competing interests: No competing interests

Additional comments

I. The original title of this response:

– Drug policy: we probably need an “irrational authority”.

Please read as:

– Drug policy: we definitely need an “irrational authority”.

II. Societies like the American Society of Addiction Medicine and American Psychiatric Association have been self-proclaimed as “rational authorities”: a euphemism created probably by complex defense mechanisms of self-preservation in a society used to suppress dissenters and reward the wrongdoers.

“The Ministry of Peace concerns itself with war, the Ministry of Truth with lies, the Ministry of Love with torture and the Ministry of Plenty with starvation. These contradictions are not accidental, nor do they result from ordinary hypocrisy: they are deliberate exercises in doublethink.”
― George Orwell, 1984

“Doublethink means the power of holding two contradictory beliefs in one’s mind simultaneously, and accepting both of them.”
― George Orwell, 1984

III. We probably need more “irrational authorities”.

Disrupted Physician 101.4–The “Impaired Physician Movement” takeover of State Physician Health Programs

These ASAM “addiction experts” have become so numerous they have been able to take over almost all the state Physician Health Programs (PHPs). Their national association—the Federation of State Physician Health Programs (FSPHP)–has a stated goal of universal acceptance of the 12-step doctrine: lifelong abstinence, and spiritual recovery as the one and only treatment, as spelled out in the “PHP Blueprint.”

Very much like Straight, Inc in the 70s and 80s, they have cast a wide net with doctors to ensnare them in an endless loop of drug testing and rehab—whether the tests are fabricated or not. The doctors will enjoy no sympathy from the public, and complaining about it is deemed a sign of your “disease.” Furthermore, ASAM recommends that physicians only be referred to “PHP approved” facilities.

The medical directors of these facilities can all be found on this list of ”Like-Minded Docs.” Surprisingly, many Like-Minded Docs were former addicts and alcoholics, some even with criminal backgrounds. There are felons and even double-felons on the list.

It’s a rehab shell game. Heads I win tails you lose.

And the program is expanding. The organization that oversees the licensing for all medical doctors, the Federation of State Medical Boards, adopted a new policy and approved the concept of “potentially impairing illness” and the Orwellian notion of “relapse without use.”

Signals for “impairment can be as benign as not having “complete accurate, and up-to-date patient medical records” according to Physician Health Services, the Massachusetts PHP. Despite the overwhelming amount of paperwork Doctors now have, incomplete or illegible records could be construed as a red flag, since as Associate Direct of PHS Judith Eaton notes “when something so necessary is not getting done, it is prudent to explore what else might be going on.” The question is, who is next?”

mllangan1's avatarDisrupted Physician

Forget what you see
Some things they just change invisibly–Elliott Smith

IMG_8923

Physician Impairment

The Sick Physician: Impairment by Psychiatric Disorders, Including Alcoholism and Drug Dependence, published by the American Medical Association’s (AMA) Council on Mental Health in The Journal of the American Medical Association in 1973,1 recommended that physicians do a better job of helping colleagues impaired by mental illness, alcoholism or drug dependence. The AMA defined an “impaired physician” as “a physician who is unable to practice medicine with reasonable skill and safety to patients because of mental illness or excessive use or abuse of drugs, including alcohol.”

Recognition of physician impairment in the 1970s by both the medical community and the general public led to the development of “impaired physician” programs with the purpose of both helping impaired doctors and protecting the public from them.

IMG_1010The 1975 media coverage of the deaths of Drs. Stewart and…

View original post 766 more words

Free Educational Webinar: How to Position Yourself as an EXPERT!

IMG_6274 2

The validity and reliability of opinions lie in their underlying methodology and evidence base. Reliance on the personal authority of any expert or group of experts is the fallacy of appeal to authority.

I have asthma but that does not make me a Pulmonologist.  That addiction “specialist” diagnosing and treating you may have 5 years prior been a proctologist; and maybe not even a very good one at that.

Somewhere there may be doctor with no post-graduate training in surgery wielding a scalpel and calling himself an expert surgeon, but it is difficult to imagine that he is a very good one.

http://disruptedphysician.com/2014/11/18/disrupted-physician-101-2-for-what-its-worth-appeal-to-authority-and-the-logical-fallacy-of-special-or-secret-knowledge/

 

Screen Shot 2014-12-30 at 1.12.01 AM

Go back

Your message has been sent

Warning
Warning
Warning
Warning

Warning.

Addiction Medicine: The Birth of a New Discipline

Somehow, I don't think this is quite what they had in mind!

Ms Bella St John's avatarContessa Bella St John


“How to Position Yourself as an EXPERT, Make More Money and Help More People, by Becoming a Published Author – Even if You Don’t Know Where to Start!” Think about it – if you need to see a chiropractor, for example, would you rather see a general chiropractor, or one who has positioned …
http://leighstjohn.com/free-educational-webinar-how-to-position-yourself-as-an-expert/

View original post

The Plan to introduce non-FDA approved drug and alcohol tests into the Healthcare system and require doctors drug-test ALL PATIENTs including students and kids!

1285610338-quack-doctor1

The Plan to introduce non-FDA approved Laboratory Developed Tests (LDTs) into the Healthcare system and require doctors drug-test ALL PATIENTs including students and kids!

The ASAM plans to introduce non-FDA approved “forensic”  Laboratory Developed Tests (LDTs) into mainstream healthcare via a loophole.    This same group introduced most of these tests through a loophole and now they want to drug-and alcohol TEST EVERYBODY including STUDENTS AND KIDS through another loophole!   These tests are of unknown reliability and accuracy.  The LDT pathway does not even require proof that the test is even valid  (i.e. that the test is actually testing for the substance it claims to be testing) but with no FDA oversight or regulation the labs can claim anything they want in marketing it and they do.

If a doctor collects a test on a “patient”  the test is rendered “clinical” rather than “forensic” and by deeming this drug-testing  “clinical” rather than “forensic”  they can then call the consequences of a positive test “treatment” rather than “punishment.  ” It is via this loophole they plan to introduce and unleash the panoply of junk-science tests currently being used on other groups who have no say in the matter (probationers, parolees, private professional monitoring groups, etc. ) onto the general population at large.    A boon for the Drug and Alcohol Testing Industry Association and the assessment and treatment industry but a bane to the rest of society.    And to prevent this from happening more people need to be talking about this.

Mandating Drug-Testing of Unknown Validity while removing the procedural safeguards of forensic drug testing: The plan to Introduce Laboratory Developed Tests into Mainstream Healthcare

Screen Shot 2013-09-04 at 6.14.30 PM

Chain-of-Custody refers to the document or paper trail showing the collection, control, transfer, analysis and disposition of laboratory tests.  It is the written documentation of a specimen from the moment of collection to the final destination to the review and reporting of the final results.   The multi-part chain-of-custody form or “custody and control” form is part and parcel of this process. It contains stickers to sign and seal the specimen so that it cannot be tampered with and the form itself is signed by the appropriate parties as the test specimen travels from place to place. Information is added to the form as it travels from person to person.  It has been given the status of a legal document as it has the ability to invalidate a specimen with incomplete information.  Once the sample is analyzed it is reviewed by a Medical Review Officer (MRO) for final review. In the case of a positive test it is the responsibility of the MRO to ascertain an intact  chain-of-custody, determine whether an alternative explanation exists for the positive test such as a prescribed medication, and then and only then report the test as a “true positive.”

The MRO looks for what are called “fatal flaws” and,  should one be present, invalidates the test.  A fatal flaw requires the test be rejected as it were never drawn.  It invalidates it and it cannot be used. screen-shot-2013-12-19-at-12-20-46-pmAny and all drug testing requires strict  chain-of-custody procedures. It documents not only the whereabouts of the specimen at any given time but the management and storage of the specimen. This is important because time and temperature can influence the results of certain tests.  One such test is alcohol.

Specimen integrity is critical in forensic drug testing, but so too is the integrity of the people involved.


Forensic Versus Clinical Drug Testing

According to the ASAM White Paper on Drug Testing, clinical drug-testing “employs the same sound procedures, safeguard, and systems of information management that are used for all other health-related laboratory tests, tests on which life-and-death medical decisions are commonly made.”  In the box below they describe the multiple safeguards in place and requirements demanded of “forensic” drug testing but do not mention the reason these uncompromising and multiple specifications exist is to protect the donor from a false accusation of drug or alcohol use.  They proceed to define “clinical drug testing” as “part of a patient examination performed for the purposes of diagnosis, treatment, and the promotion of long term recovery” noting that clinical testing “must meet the established standards of medical practice and benefit the therapeutic relationship, rather than meeting the formal legal requirements of forensic testing.”  The authors then state that the “majority of drug testing done today” includes both forensic and clinical elements using individuals on parole and probation as examples.

Screen Shot 2015-01-14 at 12.32.11 AM

From the ASAM White Paper on Drug Testing

The logical fallacy here is striking.  It is comparing apples and oranges.  After detailing the specific quality assurance safeguards designed to prevent the donor of a drug or alcohol test from being falsely accused of illicit use, the authors give a general  definition and purpose of  “clinical” testing  then state that when testing for drugs the systems in place are up to snuff as they are already being used to make  “life-and-death medical decisions.”  The take-home message is that “forensic” testing is unnecessary hyperbole designed for legal challenges. The clinical lab  systems in place are used for critically  important testing and can therefore be used for drug-testing–after all, parolees and probationers don’t require it.

Forensic guidelines were developed in collaboration with occupational and environmental medicine specialists, clinical and forensic toxicologists, pathologists and others and the recommended  requirements agreed upon by this consortium exists solely to  assure validity and accuracy in the testing process.  These requirements exist to protect the donor and If the “clinical” testing context fit the bill then “forensic” testing would not have evolved.

Labs ordered clinically in the course of patient care are interpreted within the context of multiple other pieces of data.  Lab errors occur all the time and are interpreted in that context. Oftentimes a lab will not fit with the clinical picture and, when that happens, a repeat lab is ordered for verification.  Specimens get collected in the wrong tube and specimens get lost but in the clinical setting they simply get reordered and there are no consequences to patient care.   In contrast drug testing is an all-or-none one-shot test and the results have consequences. It is for that reason they must be valid.  Chain-of-custody and MRO review are critical and that is why most drug-testing programs follow the forensic protocol.  And the example of non-forensic drug-testing  parolees and probationers is misleading.   Any Employee Assistance Program that has a union or some other group looking out for their best interests uses strict “forensic” guidelines.   Parolees and probationers have no power  and have no choice.  Besides, the  National Association of Drug Court Professionals uses the Laboratory Developed Tests these same people introduced to test  individuals on probation or parole in the criminal justice system just as they do in the PHPs.

The  ASAM White Paper:

 “Encourages wider and “smarter” use of drug testing within the practice of medicine and, beyond that, broadly within American society. Smarter drug testing means increased use of random testing* rather than the more common scheduled testing,* and it means testing not only urine but also other matrices such as blood, oral fluid (saliva), hair, nails, sweatand breath when those matrices match the intended assessment process. In addition, smarter testing means testing based upon clinical indication for a broad and rotating panel of drugs”

As a physician-patient relationship renders drug testing “clinical” rather than “forensic” the consequences become “treatment” rather than “discipline.”  And that is the real reason behind all of this.    A positive “forensic” test in most employee random drug screening programs today will result in an “assessment” for substance abuse.  Most EAPs allow a choice in where that assessment takes place.  The model this system is based on, Physician Health Programs. do not allow choice as evaluations are mandated to “PHP-approved” assessment centers; a rigged game.

A positive “clinical” test will result in the same thing under the ASAM White Paper proposal.  But the assessment will be at an ASAM facility and if a Substance Use Disorder (SUD) is confirmed it will result in mandated abstinence of all substances (including alcohol) and lifelong spirituality involving 12-step recovery   And by using the healthcare system as a loophole and calling this testing “clinical” rather than “forensic” the ASAM will have successfully introduced widespread testing of a variety of Laboratory Developed Tests (LDTs) of unknown validity while removing  the safeguards provided by forensic testing including chain-of-custody and MRO review.

 

Screen Shot 2014-02-25 at 1.06.55 PM

Go back

Your message has been sent

Warning
Warning
Warning
Warning

Warning.

Screen Shot 2014-02-25 at 1.04.35 PM

Junk Science and the Need for Regulatory Oversight of Forensic Laboratory Developed Tests

Screen Shot 2015-01-12 at 10.43.08 PM

Screen Shot 2014-02-21 at 11.38.29 AM


Laboratory Developed Tests

Questions about the accuracy and marketing of Laboratory Developed Tests (LDTs) have led to the current debate whether the U.S. Food and Drug Administration (FDA) should regulate a subset of diagnostic tests currently exempted from oversight. Designed to bring clinical tests to market that the costly FDA process would otherwise preclude, such as those for rare diseases, the LDT pathway bypasses Federal regulation and accountability.  Questions about the validity of these tests have raised concerns over patient safety and a call for oversight.  Among those asking for regulation are Massachusetts Senators Edward J. Markey and Elizabeth Warren.

Opponents of regulation argue the LDT  pathway enables new and pioneering tests to be developed quickly and improve patient care.  A recent viewpoint piece published in JAMA opposing regulation noted such advances have occurred “in large part because of the nimbleness of relatively small clinical and academic laboratories that can quickly respond to new medical findings and patient needs by rapidly and safely developing and improving laboratory-developed tests.”

But the LDT pathway does not require proof of test validity, that the test is actually testing for what it claims to be testing, and with no FDA oversight a lab can claim any validity it wants in marketing the test.  There is no accountability.    Proponents of  regulation argue that this lack of oversight is a direct threat to patient safety and, as an opposing viewpoint piece in JAMA notes, a “patient’s life or death could hinge on whether a single, unregulated diagnostic test result is meaningful.”

The debate has focused on the reliability and validity of a number of clinical tests currently marketed with unverified claims of accuracy such as those used for prenatal screening and Lyme disease.  Notably absent from the discussions are the vast number of  Laboratory Developed Tests tests being used for “forensic” drug and alcohol testing with the current FDA draft guidance stating simply:

  • At this time, FDA will continue to defer oversight of the use of these tests in the forensics (law enforcement) setting to the existing system of legal controls, such as the rules of evidence in judicial proceedings and other protections afforded through the judicial process.”


The Birth of EtG:  The Introduction and Marketing of Laboratory Developed Tests for “Forensic” Drug Testing  Via a Lucrative Loophole

Numerous “forensic” tests of unknown validity using urine, blood, hair, fingernails breath and saliva have been developed and brought to market as LDTs since the first one was introduced in 2003 when ASAM physician Dr. Gregory Skipper,  then Medical Director of the Alabama Physicians Health Program,  “convinced the initial lab in the USA, NMS near Philadelphia to start performing EtG testing.”1   With essentially no evidence base Skipper then claimed the alcohol biomarker “appeared to be 100 percent specific” in detecting covert use of alcohol for several days after ingestion based on a study he coauthored that involved a mere 35 forensic psychiatric inpatients in Germany, all male2  

Screen Shot 2014-02-24 at 10.08.19 PMUsing an arbitrary cutoff level of 100 ug/L the EtG was marketed as a valid and reliable test and blindly tested on those being monitored by programs not beholden to the strict protocol and procedure dictated by the Mandatory Guidelines for Federal Workplace Drug Testing that most Employee Assistance Programs (EAPs) adopted.  In other words, the test was used on those who possessed little power or had their power removed.

The test was  subsequently found to be so sensitive that it could measure incidental exposure to alcohol in foods, over the counter cold medications, mouthwash3,4, hand sanitizer gel5, and nonalcoholic wine.6 Sauerkraut and bananas have even been shown to cause positive levels.7

Slide25

Shortly after the EtG debuted, complaints began to accumulate from individuals testing positive who adamantly proclaimed they did not drink.  Steadfast in their trust of expert opinion and the claimed accuracy of  EtG, the complaints of the accused were largely disregarded by those doing the monitoring.   People lost their licenses, jobs, careers, and reputations. Others lost their freedom or had their children taken away. It is unknown how many died by suicide.

There have been multiple  lawsuits filed since the introduction of the EtG including a class-action suit, but these were inevitably met with a well-funded and deep legal defense and their “experts.” The labs have taken a  “stand your ground” position yielding either dismissals or in favor of the defense.   As a new to the market  lab with no prior evidence-based research in forensic testing prior to its implementation and use for forensic testing, the proponents of EtG testing had no meaningful opposition in terms of a scientific body of facts and evidence and no credible voice to present it.  With the only “experts”  in EtG validity being those  who introduced and promoted its use there were no counter-forces.  Those suffering the consequences of a false-positive test had no recourse.  But as the toll of mayhem increased  it eventually reached a tipping-point where others began to take notice.

Page from the Talbott Recovery Center  list of products containing alcohol that doctors are required to avoid due to interference with EtG testing

Page from the Talbott Recovery Center list of products containing alcohol that doctors are required to avoid due to interference with EtG testing

In 2006 the Wall Street Journal reported the problems with the EtG to the general public,8 and SAMHSA issued an advisory stating that “legal or disciplinary action based solely on a positive EtG…. is inappropriate and scientifically unsupportable at this time. These tests should currently be considered as potential valuable clinical tools, but their use in forensic settings is premature.”9

Since that time Skipper has served as expert witness in close to 46 administrative hearings 22 criminal  14 custody and 1 Federal class action suit.

Unknown-20

But this did not stop the Federation of State Physician Health Programs  from using the EtG on physicians being monitored. Instead they instructed doctors to avoid anything potentially containing alcohol including hand sanitizer which a 2011 study found could result in EtG concentrations of almost 2000 ug/L. 10 To continue to justify the use of EtG they added other LDTs as confirmation tests of LDTs such as EtS and PEth– Junk Science to confirm  junk science. Nonsensical smoke-and-mirrors antithetical to science and evidence-based medicine.

Since the birth of the EtG a variety of tests have been introduced and marketed as LDTs utilizing nails, blood, hair, breath and urine—all with unknown validity but marketed without constraint.  No regulation, oversight or accountability exists.

The newest gadget they are using on doctors is the Cellular Digital Photo Breathalyze which he is promoting in the same manner as the EtG after a study he co-authored with Robert Dupont on just 12 subjects.


Expanding Laboratory Developed Tests to Test Everyone:   The ASAM White Paper on Drug-Testing and the  “New Paradigm” 

Although the current use of these tests is limited to the criminal justice system and professional monitoring programs this may soon change as the American Society of Addiction Medicine is proposing a “new paradigm” of zero-tolerance random widespread drug and alcohol testing. This is outlined  in the ASAM White Paper on Drug Testing and described by Robert Dupont in his keynote speech  before the Drug and Alcohol Testing Industry Association (DATIA) annual conference in 2012.

The ASAM White paper states drug testing is “vastly underutilized” throughout healthcare and describes the use of drug testing “within the practice of medicine and, beyond that, broadly within American Society.”

As the consequences of a single unregulated “forensic” test result can be grave, far-reaching and even permanent it is critical that these tests be included in the debate on regulation of LDTs.

Evidence based medicine is not restricted to randomized trials and meta-analyses. It involves tracking down the best external evidence with which to answer our clinical questions.11

Expert opinion is the lowest level of evidence available in the EBM paradigm.12,13   Fortunately, the scientific method and Cochrane type critical analysis of the available evidence is  a tool to help people progress toward the truth despite their susceptibilities to unconscious confirmatory bias or conscious confirmatory distortion .14  Unfortunately, no one has used these tools address they panoply of tests of unknown validity that have already entered the market ; poised to be used on virtually everyone.

  1. Skipper G. Exploring the Reliability, Frequency, and Methods of Drug Testing: What is Enough to Ensure Compliance?:   Alcohol Markers and Devices. 2013; http://www.fsphp.org/Skipper, Exploring the Reliability Frequency and Methods 2 Presentation.pdf.
  2. Wurst FM, Vogel R, Jachau K, et al. Ethyl glucuronide discloses recent covert alcohol use not detected by standard testing in forensic psychiatric inpatients. Alcohol Clin Exp Res. Mar 2003;27(3):471-476.
  3. Costantino A, Digregorio EJ, Korn W, Spayd S, Rieders F. The effect of the use of mouthwash on ethylglucuronide concentrations in urine. Journal of analytical toxicology. Nov-Dec 2006;30(9):659-662.
  4. Reisfield GM, Goldberger BA, Pesce AJ, et al. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. Journal of analytical toxicology. Jun 2011;35(5):264-268.
  5. Rosano TG, Lin J. Ethyl glucuronide excretion in humans following oral administration of and dermal exposure to ethanol. Journal of analytical toxicology. Oct 2008;32(8):594-600.
  6. Hoiseth G, Yttredal B, Karinen R, Gjerde H, Christophersen A. Levels of ethyl glucuronide and ethyl sulfate in oral fluid, blood, and urine after use of mouthwash and ingestion of nonalcoholic wine. J Anal Toxicol. Mar 2010;34(2):84-88.
  7. Musshoff F, Albermann E, Madea B. Ethyl glucuronide and ethyl sulfate in urine after consumption of various beverages and foods–misleading results? Int J Legal Med. Nov 2010;124(6):623-630.
  8. Helliker K. A test for alcohol–and its flaws. The Wall Street Journal2006.
  9. Administration SAaMHS. The role of biomarkers in the treatment of alcohol use disorders. In: Advisory SAT, ed2006:1-7.
  10. Reisfield GM, Goldberger BA, Crews BO, et al. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. Journal of analytical toxicology. Mar 2011;35(2):85-91.
  11. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. Jan 13 1996;312(7023):71-72.
  12. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. Feb 25 2009;301(8):868-869.
  13. Straus SE, Green ML, Bell DS, et al. Evaluating the teaching of evidence based medicine: conceptual framework. BMJ. Oct 30 2004;329(7473):1029-1032.
  14. Haack S. Defending Science–Within Reason: Between Scientism and Cynicism. Amherst, N.Y.: Prometheus Books; 2003.

Screen Shot 2014-02-15 at 4.39.03 PM

IMG_0701

quote-a-liar-sees-lies-said-taleswapper-even-when-they-aren-t-there-just-as-a-hypocrite-sees-orson-scott-card-216626